Iambic Therapeutics has filed a notice of an exempt offering of securities to raise $66,500,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Iambic Therapeutics is raising up to $66,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Iambic Therapeutics
Iambics mission is to make better technology for better medicines. By utilizing molecular superintelligence integrating proprietary AI with automated, scalable chemistry and biology experimentation our platform is designed to address the totality of drug discovery and development. The utility of our platform has been demonstrated by the discovery of a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine.

To learn more, visit https://www.iambic.ai/
LinkedIn: https://www.linkedin.com/company/iambic-ai/

Contact:
Tom Miller, Chief Executive Officer
https://www.linkedin.com/in/thomas-miller-322a8521/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.